Semaglutide Market is Estimated To Witness High Growth Owing To Trends of Increasing Obesity Prevalence
Market
Overview:
Semaglutide
is a GLP-1 receptor agonist used for glycemic control in adults with type 2
diabetes and for chronic weight management in adults with obesity or overweight
and at least one weight-related comorbidity. Semaglutide helps in reducing
appetite, decreasing food consumption and slowing down digestion. It plays a
vital role in controlling blood sugar levels and managing obesity by inducing
weight loss.
Market key trends:
The global semaglutide market is primarily driven by the increasing
prevalence of obesity worldwide. As per the data provided by the World Health
Organization (WHO), around 13% of the world's adult population was obese in
2016. Moreover, approximately 650 million adults were obese in 2016 globally.
This has increased the demand for effective drugs for weight management and
glycemic control such as semaglutide. Furthermore, increasing approval of
semaglutide for new therapeutic indications by regulating authorities around
the world is also estimated to boost the market growth over the forecast
period. For instance, in November 2021, semaglutide (Ozempic) received approval
from the U.S. FDA for chronic weight management.
Porter’s Analysis
Threat of new entrants: The Semaglutide
Market Demand has moderate threat from new entrants due to high capital
requirement for R&D and manufacturing of products.
Bargaining power of buyers: The bargaining power of buyers is moderate owing to
availability of substitute products. However, patented drugs have some
advantage.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power
in semaglutide market as there exist large number of suppliers.
Threat of new substitutes: Threat from new substitutes is moderate as
researchers are continuously making efforts to develop improved substitutes.
Competitive rivalry: High due to presence of many global and local players.
SWOT Analysis
Strength: Semaglutide is well-established drug with proven efficacy and
safety. growing prevalence of diabetes and obesity worldwide.
Weakness: Requirement of injections and high cost of treatment. Need for
continuous monitoring of glucose level.
Opportunity: Increase in healthcare expenditure in developing nations. Unmet
needs in emerging markets.
Threats: Patent expiration of blockbuster drugs. Stringent regulatory
requirements.
Key Takeaways
The global semaglutide market is expected to witness high growth at a CAGR of
11% over the forecast period due to increasing prevalence of diabetes and
obesity. By 2030, the market size is projected to reach US$ 35 Bn.
Regionally, North America is anticipated to dominate the global market
throughout the forecast period. This is attributed to growing obesity rates,
availability of advanced healthcare facilities and presence of key market
players in the region. Europe is also among the prominent markets and is likely
to exhibit growth at a CAGR of over 10% during 2023-2030.
Key players operating in the semaglutide market are Novo Nordisk A/S, HEC
Pharma Co., Shenzhen JYMed Technology Co. Ltd., Bachem Holding AG. Players
adopt strategies such as partnerships, mergers, acquisitions and new product
launches to increase their revenue share and geographical presence in the
market.
Read More:
Comments
Post a Comment